Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

Optimism for Lilly’s Trulicity CVOT but hesitance on prior GLP-1 CVOTs benefits

Eli Lilly’s approved type 2 diabetes (T2D) medication Trulicity (dulaglutide) is in a study to assess its impact on cardiovascular risk and triggered mostly cautious optimism for success. Yet, interviewed T2D experts also noted uncertainty still prevails given similar drugs have shown varying results in their respective cardiovascular trials.

Free download worth over $5000
Download our 2018 Technology, Media and Telecoms Predictions Report

Worth up to $5,850

In this report, we look at the 30 big tech themes identifying winners and losers for each theme. This report will impact all industries helping:

  • CEOs/Senior Staff: in all industries understand the disruptive threats to their competitive landscape
  • Investors: Helps fund managers focus their time on the most interesting investment opportunities in global technology, media and telecoms

Go Top